• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Vaccines, Blood & Biologics

  • Print
  • Share
  • E-mail

Section Contents Menu

Vaccines

Telephone Conference Memorandum - 8/3/2007 - AFLURIA

TELEPHONE CONFERENCE MEMORANDUM

STN 125254/0:CTD BLA for Influenza Virus Vaccine
SPONSOR:CSL Limited
PRODUCT:Influenza Virus Vaccine
DATE:August 3, 2007

CBER REPRESENTATIVE:
Katherine Berkhousen
Rakesh Pandey

CSL REPRESENTATIVE:
Paul Hartman
Tel: 610-878-4644

SUMMARY:

CSL contacted to discuss the following CMC concerns:

  1. --------------------------------------------------------------------------------------------------------------------------------------
    --------------------------------------------------------------------------------------------------------------------------------------
    --------------------------------------------------------------------------------------------------------------------------------------
    --------------------------------------------------------------------------------------------------------------------------------------
    --------------------------------------------------------------------------------------------------------------------------------------
    --------------------------------------------------------------------------------------------------------------------------------------
    ---------------------------------------------------------------
  2. --------------------------------------------------------------------------------------------------------------------------------------
    --------------------------------------------------------------------------------------------------------------------------------------
    --------------------------------------------------------------------------------------------------------------------------------------
    --------------------------------------------------------------------------------------------------------------------------------------
    --------------------------------------------------------------------------------------------------------------------------------------
    --------------------------------------------------------------------------------------------------------------------------------------
    --------------------------------------------------------------------------------------------------------------------------------------
    --------------------------------------------------------------------------------------------------------------------------------------
    --------------------------------------------------------------------------------------------------------------------------------------
    --------------------------------------------------------------------------------------------------------------------------------------
    --------------------------------------------------------------------------------------------------------------------------------------
    --------------------------------------------------------------------------------------------------------------------------------------
    ------------------------
  3. --------------------------------------------------------------------------------------------------------------------------------------
    -------------------------------------------------------------------------------------------------------------------------------